Accutane (Isotretinoin) Side Effects, Withdrawal, and Discontinuation Syndrome: What Patients and Clinicians Need to Know

Does isotretinoin cause withdrawal or a discontinuation syndrome?

The Warnings and Precautions list in the Absorica label has no withdrawal or discontinuation syndrome heading [1]. The older Accutane-format label instead describes most adverse reactions in clinical trials as reversible when therapy was discontinued, with some persisting after cessation [2]. Isotretinoin is a retinoid that inhibits sebaceous gland function and keratinization, and the label describes the fall in sebum secretion as temporary and related to dose and duration of treatment [1].

The label also notes that among patients who reported depression, some said it subsided when the drug was stopped and returned when the drug was restarted [1].

What side effects does the Accutane label list?

The Accutane prescribing information includes warnings for psychiatric disorders, pseudotumor cerebri, serious skin reactions, pancreatitis and lipid elevations [2]. Its adverse reactions section lists hepatitis, inflammatory bowel disease, musculoskeletal abnormalities including bone mineral density decreases and premature epiphyseal closure, hearing impairment, corneal opacities and decreased night vision [2]. Cheilitis and hypertriglyceridemia are described as usually dose related [2].

The Absorica and Absorica LD label, which covers those two specific products, lists warnings and precautions for embryo-fetal toxicity, the iPLEDGE REMS, non-substitutable products, psychiatric disorders, intracranial hypertension, serious skin reactions, pancreatitis, lipid abnormalities, hearing impairment, hepatotoxicity, inflammatory bowel disease, musculoskeletal abnormalities, ocular abnormalities, hypersensitivity reactions and laboratory monitoring [1].

Skin, lips, eyes and sun sensitivity

Dry lips, dry skin, dry eye, nosebleeds and dermatitis all appear among the most common reactions, reported in 5% or more of patients [1]. Dry nose, dry mouth, peeling of the palms and soles, and hair abnormalities are also listed [1][2].

Sun exposure gets specific attention. The label counsels avoiding prolonged exposure to UV rays or sunlight [1], and the Medication Guide says to avoid sunlight and tanning machines as much as possible because the drug may make skin more sensitive to light [2]. The adverse reaction lists include photoallergic and photosensitizing reactions and increased sunburn susceptibility [1].

The label says to avoid wax epilation and skin resurfacing procedures during treatment and for at least 6 months afterward because of scarring [1][2].

Lipids, liver and pancreas

In clinical trials, marked elevations of serum triglycerides were reported in approximately 25% of patients receiving isotretinoin, about 15% developed a decrease in high-density lipoproteins, and about 7% showed an increase in cholesterol; these effects were reversible upon stopping the drug [2]. The Absorica label calls for a fasting lipid profile and liver function tests in all patients before use [1], and the older label directs lipid testing before treatment and then at intervals until the lipid response is established, usually within 4 weeks [2].

In a retrospective cohort of 13,772 patients aged 13 to 50 on oral isotretinoin, the cumulative incidence of new abnormalities in people with normal baseline values was 44% for triglycerides, 31% for total cholesterol and 11% for transaminase; moderate to severe lipid and transaminase abnormalities were generally transient and reversible [5].

Acute pancreatitis has been reported in patients with either elevated or normal serum triglycerides, and the label says to discontinue treatment if pancreatitis symptoms occur [1][2]. The older label also notes that some patients reversed triglyceride elevation with weight reduction, restriction of dietary fat and alcohol, and a lower dose while continuing treatment [2].

Mood and psychiatric effects

The boxed warning on isotretinoin concerns life-threatening birth defects, not mental health; psychiatric effects appear under Warnings and Precautions [1]. The drug may cause depression, psychosis and, rarely, suicidal ideation, suicide attempts, suicide, and aggressive or violent behaviors [1]. Prescribers are told to ask about psychiatric history before treatment and to assess for depression, mood disturbance, psychosis or aggression at each visit [1]. The label says that stopping treatment alone may be insufficient and that further evaluation may be necessary [1].

A 2017 meta-analysis of 31 studies found that the change in depression scores from baseline did not differ significantly between patients on isotretinoin and those on alternative treatment (standardized mean difference -0.334, 95% CI -0.680 to 0.011), that mean depression scores fell from baseline (standardized mean difference -0.335, 95% CI -0.498 to -0.172), and that the prevalence of depression after treatment declined (relative risk 0.588, 95% CI 0.382 to 0.904). The authors noted that no randomized controlled trials were included [6].

Ocular, bone, bowel and other serious reactions

Intracranial hypertension, or pseudotumor cerebri, is listed as a warning, and the label says to avoid combining isotretinoin with tetracyclines because some cases involved that combination [1]. Serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis are listed, with instructions to monitor and discontinue if they occur [1]. Hearing impairment is listed, with referral to specialized care [1]. For visual symptoms, including corneal opacities and decreased night vision, the label says to discontinue and refer for an ophthalmological exam [1].

Musculoskeletal warnings include arthralgia, back pain, decreases in bone mineral density and premature epiphyseal closure [1]. In a 16- to 20-week course at roughly 1 mg/kg in 217 adolescents aged 12 to 17, there was no clinically significant mean change in bone mineral density at the lumbar spine (+1.4%) or total hip (-0.26%) [7].

Inflammatory bowel disease is listed as a warning, with instructions to discontinue for abdominal pain, rectal bleeding or severe diarrhea [1]. A population-based case-control study found that 1.2% of people with IBD had used isotretinoin before diagnosis, statistically similar to 1.1% of matched controls [8].

What happens after the last dose

After stopping, acne relapse is a documented post-course outcome. In a Quebec cohort of 17,351 first-time isotretinoin users assembled between 1984 and 2003, 41% later received an antiacne medication, the study's definition of relapse, and 26% received a second isotretinoin course [3]. The label does not recommend starting a second course before a 2-month waiting period because acne may keep improving after a 15- to 20-week course [1].

The Absorica label gives a daily dose and course length but does not set a cumulative mg/kg target: 0.5 to 1 mg/kg/day in two divided doses for 15 to 20 weeks (Absorica LD: 0.4 to 0.8 mg/kg/day), with up to 2 mg/kg/day of Absorica (1.6 mg/kg/day of Absorica LD) in very severe adult disease [1]. A 2026 single-centre randomized trial compared cumulative doses of 120 and 150 mg/kg and found no significant difference in lesion counts or severity (all p>0.20), with 12-month relapse of 26.7% versus 32.3% (p=0.619) [9].

A small set of reactions can outlast the course. The label lists decreased night vision which may persist, alopecia which in some cases persisted, and sexual dysfunction that may continue after discontinuation [1].

Some iPLEDGE duties also continue. The label includes a blood-donation restriction during treatment and for 1 month after discontinuation [1]. The label also includes pregnancy testing after treatment [1] and says breastfeeding is not recommended during treatment and for at least 8 days after the last dose [1].

Drug interactions

The label advises avoiding tetracyclines with isotretinoin because of intracranial hypertension cases involving the combination [1]. It also advises avoiding vitamin A supplements because isotretinoin is closely related to vitamin A [1]. Micro-dosed progesterone minipills are described in the older label as possibly an inadequate contraceptive method during treatment, and patients are warned not to self-medicate with St. John's wort because of a suggested interaction with hormonal contraceptives [2]. Isotretinoin did not cause clinically significant pharmacokinetic changes in norethindrone and ethinyl estradiol given together as an oral contraceptive, and it is not known whether it interacts with other oral contraceptives [1].